Sutent® Fails to Show Benefit in Metastatic Colorectal Cancer
(07/01/2009)
The combination of the targeted therapy Sutent® (sunitinib) and FOLFIRI chemotherapy did not result in better progression-free survival than FOLFIRI alone among patients with metastatic colorectal cancer, prompting a Phase III clinical trial of the combination treatment to be stopped early. This information was made available in a press release from Pfizer.
CT Colonography May Be Appropriate Screening Test for Some High-risk Individuals
(06/22/2009)
Among people at increased risk of colorectal cancer, computed tomographic (CT) colonography correctly classified 85% of the people with advanced adenomas or cancer and 88% of the people without advanced adenomas or cancer. These results were published in the Journal of the American Medical Association.
Age and Illness Increase Colonoscopy Risks
(06/18/2009)
Although the risk of complications from colonoscopy is low, risk increases among the very elderly and among those with certain chronic health conditions. These results were published in the Annals of Internal Medicine.
Preemptive Skin Treatment Reduces Skin Toxicity Associated with Vectibix® in Patients with Metastatic Colorectal Cancer
(06/09/2009)
Early skin treatment that is initiated prior to the start of EGFR treatment with Vectibix® (panitumumab) reduces the incidence and severity of skin toxicity and improves quality of life in patients with metastatic colorectal cancer, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Surgery Unnecessary for Most Patients with Metastatic Colorectal Cancer
(06/02/2009)
Patients with newly diagnosed metastatic colorectal cancer do not need to undergo surgical removal of their tumor unless the tumor is causing complications, according to the results of a study presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
More...
Screening/Prevention
CT Colonography May Be Appropriate Screening Test for Some High-risk Individuals
(06/22/2009)
Among people at increased risk of colorectal cancer, computed tomographic (CT) colonography correctly classified 85% of the people with advanced adenomas or cancer and 88% of the people without advanced adenomas or cancer. These results were published in the Journal of the American Medical Association.
Age and Illness Increase Colonoscopy Risks
(06/18/2009)
Although the risk of complications from colonoscopy is low, risk increases among the very elderly and among those with certain chronic health conditions. These results were published in the Annals of Internal Medicine.
Coffee Does Not Decrease Risk of Colorectal Cancer
(05/04/2009)
Contrary to the results of several previous studies, coffee consumption does not appear to reduce the risk of colorectal cancer, according to the results of a study published in the International Journal of Cancer.
Aspirin Helps Prevent Colorectal Adenomas
(03/11/2009)
Daily use of aspirin may reduce the risk of colorectal adenomas, especially advanced lesions, according to the results of a study published in the Journal of the National Cancer Institute.
Diet Rich in Calcium May Reduce Risk of Colorectal Cancer
(03/06/2009)
A diet that is high in calcium may be associated with a reduced risk of cancer, especially colorectal cancer, according to the results of a study published in the Archives of Internal Medicine.
More...
Adjuvant (I-III, A-C)
No Benefit of Avastin® in Early-stage Colon Cancer
(06/01/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), addition of the targeted therapy Avastin® (bevacizumab) to post-surgery chemotherapy does not improve disease-free survival among patients with early-stage colon cancer. These results were previously made available in a press release from Roche.
Addition of Eloxatin® to Adjuvant Chemotherapy Improves Colon Cancer Outcomes
(05/22/2009)
The addition of Eloxatin® (oxaliplatin) to adjuvant (post-surgery) chemotherapy with fluorouracil and leucovorin improves survival among patients with Stage II or Stage III colon cancer. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Oncotype DX® Colon Cancer Test Predicts Recurrence Risk
(06/03/2009)
According to the results of a study that will be presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), the Oncotype DX® colon cancer test estimates the risk of cancer recurrence among patients with Stage II colon cancer. This test may eventually help guide colon cancer treatment decisions.
Avastin® Fails to Provide Benefit in Early-stage Colon Cancer
(04/22/2009)
According to the results of a Phase III clinical trial, the addition of the targeted therapy Avastin® (bevacizumab) to post-surgery chemotherapy does not reduce the risk of cancer recurrence among patients with early-stage colon cancer. These results were made available in a press release from Roche.
Oncotype DX® Colon Cancer Assay Predicts Risk of Cancer Recurrence
(04/16/2009)
According to a press release from Genomic Health, the Oncotype DX® colon cancer assay—a genomic test similar to one already in use for breast cancer—has been shown to predict the risk of cancer recurrence among patients with Stage II colon cancer. This test may eventually help guide colon cancer treatment decisions.
More...
Stage IV (D)/Relapsed
Sutent® Fails to Show Benefit in Metastatic Colorectal Cancer
(07/01/2009)
The combination of the targeted therapy Sutent® (sunitinib) and FOLFIRI chemotherapy did not result in better progression-free survival than FOLFIRI alone among patients with metastatic colorectal cancer, prompting a Phase III clinical trial of the combination treatment to be stopped early. This information was made available in a press release from Pfizer.
Preemptive Skin Treatment Reduces Skin Toxicity Associated with Vectibix® in Patients with Metastatic Colorectal Cancer
(06/09/2009)
Early skin treatment that is initiated prior to the start of EGFR treatment with Vectibix® (panitumumab) reduces the incidence and severity of skin toxicity and improves quality of life in patients with metastatic colorectal cancer, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Surgery Unnecessary for Most Patients with Metastatic Colorectal Cancer
(06/02/2009)
Patients with newly diagnosed metastatic colorectal cancer do not need to undergo surgical removal of their tumor unless the tumor is causing complications, according to the results of a study presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
Study Assesses Risk of Gastrointestinal Perforation in Patients Treated with Avastin®
(05/28/2009)
Gastrointestinal perforation is a potentially serious side effect of the targeted therapy Avastin® (bevacizumab). To explore how frequently this side effect occurs, a study published in Lancet Oncology evaluated information from 17 clinical trials. The results indicate that Avastin users are roughly twice as likely as nonusers to experience gastrointestinal perforation but that the risk appears to vary by Avastin dose and tumor type.
Erbitux® plus FOLFIRI Reduces Time to Recurrence as First-line Treatment of Metastatic Colorectal Cancer
(04/09/2009)
The addition of Erbitux® (cetuximab) to FOLFIRI chemotherapy reduces the risk of progression in patients with metastatic colorectal cancer, according to the results of a study published in the New England Journal of Medicine.
More...